210 related articles for article (PubMed ID: 25179838)
1. Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.
Park IH; Kang JH; Lee KS; Nam S; Ro J; Kim JH
Tumour Biol; 2014 Dec; 35(12):12173-80. PubMed ID: 25179838
[TBL] [Abstract][Full Text] [Related]
2. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
Hoppe R; Achinger-Kawecka J; Winter S; Fritz P; Lo WY; Schroth W; Brauch H
Eur J Cancer; 2013 Nov; 49(17):3598-608. PubMed ID: 23968733
[TBL] [Abstract][Full Text] [Related]
7. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer.
Shao X; Huang P; Shi L; Lei L; Cao W; Chen Z; Wang X; Zheng Y
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775882
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer.
Anwar SL; Sari DNI; Kartika AI; Fitria MS; Tanjung DS; Rakhmina D; Wardana T; Astuti I; Haryana SM; Aryandono T
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1223-1228. PubMed ID: 31030498
[TBL] [Abstract][Full Text] [Related]
11. Identification of circulating microRNA signatures for breast cancer detection.
Chan M; Liaw CS; Ji SM; Tan HH; Wong CY; Thike AA; Tan PH; Ho GH; Lee AS
Clin Cancer Res; 2013 Aug; 19(16):4477-87. PubMed ID: 23797906
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
[TBL] [Abstract][Full Text] [Related]
13. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
[TBL] [Abstract][Full Text] [Related]
14. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
[No Abstract] [Full Text] [Related]
15. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
16. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
17. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer.
Cheng C; Fu X; Alves P; Gerstein M
Genome Biol; 2009; 10(9):R90. PubMed ID: 19723326
[TBL] [Abstract][Full Text] [Related]
18. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status.
Zhou X; Marian C; Makambi KH; Kosti O; Kallakury BV; Loffredo CA; Zheng YL
PLoS One; 2012; 7(6):e39011. PubMed ID: 22723919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
